1. The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 Dearing
- Author
-
Ki-Hoon Song, Xiao Xiang, So Hyun Lee, Jong Kyu Woo, Gansukh Enkhtaivan, Carlos Rios Giraldo, You-Rim Lee, Yeo Jin Jeong, Salar Pashangzadeh, Negar Sharifi, An-Dao Yang, Huy-Dung Hoang, Nam-Hyuk Cho, Yeon-Sook Lee, Dong Guk Park, and Tommy Alain
- Subjects
MT: Regular Issue ,reovirus variant ,truncated Sigma1 ,determinant for reovirus oncolysis ,ICI combination ,reduction of neutralization ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The mammalian reovirus Type 3 Dearing (T3D) is a naturally occurring oncolytic virus. We previously identified a T3D variant isolated from persistently infected cancer cells that has a premature stop codon mutation in the S1 gene, generating a truncated σ1-attachment protein that lacks the globular head. We now report on the molecular characterization of this variant, named RP116, and assess its antitumor potential in human cancer cells and syngeneic mouse models. RP116 replicates efficiently in several cancer cell lines, shows reduced dependency for the JAM-A receptor, significantly decreases tumor growth in syngeneic models when injected either intratumorally or intravenously, and generates long-term cures and immune memory in combination with checkpoint inhibitors. Finally, we demonstrate that RP116 infection in mice leads to reduced production of neutralizing antibodies directed against reovirus T3D, preserving the efficacy of subsequent reovirus treatment. These results establish the value of developing RP116 as an additional oncolytic reovirus platform.
- Published
- 2024
- Full Text
- View/download PDF